TPT 8.09 Safety of Apixaban for Postoperative Venous Thromboembolism Prophylaxis After Bariatric Surgery: A Single-Centre Retrospective Cohort Study

Clicks: 3
ID: 324086
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #345 of 432 articles by views in the british journal of surgery

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 432 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Venous thromboembolism (VTE) is a major postoperative concern after bariatric surgery, and the optimal strategy for extended chemoprophylaxis remains uncertain. Direct oral anticoagulants such as apixaban offer convenience, yet real-world safety data in bariatric patients are limited. This study evaluated the safety of apixaban for post-discharge VTE prophylaxis in a high-volume tertiary centre. Methods We performed a retrospective cohort study at the Bariatric Centre of Kafrelsheikh University Hospitals, Egypt. Adults undergoing primary or revisional bariatric surgery between January 1, 2022 and May 30, 2025 who received apixaban prophylaxis were included (n=540). Apixaban 2.5 mg twice daily was initiated about 72 hours postoperatively and continued for 30 days. Outcomes at 30 and 90 days included any adverse event (AE), VTE, major bleeding, clinically relevant non-major bleeding (CRNMB), skin reactions, readmission, return to theatre, transfusion, and mortality. Results AEs occurred in 28 patients (5.2%). CRNMB primarily vaginal bleeding was most common (3.0%), followed by skin rash (2.2%). No VTE or major bleeding events were detected; the upper 95% confidence bound for these zero-event outcomes was 5.6 per 1000. All AEs occurred in female patients, showing a significant association with sex (P=0.0084). Conclusions A 30-day postoperative course of apixaban showed a favourable short-term safety profile in this 540-patient cohort, with no observed VTE or major bleeding. Apixaban appears to be a practical option for extended prophylaxis, with attention to counselling women regarding non-major bleeding risk.
Reference Key
openalex_W7172540074 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mohamed Abosheisha
Journal the british journal of surgery
Year 2026
DOI
10.1093/bjs/znag087.267
URL
https://doi.org/10.1093/bjs/znag087.267
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.